Dr. Weeks’ Comment: Now targeting the cancer STEM cells is becoming profitable…
“…OncoMed has seven anti-cancer therapeutic candidates in clinical development…”
OncoMed Pharmaceuticals to Report Financial Results for the Third Quarter on Tuesday, November 1, 2016
By GlobeNewswire, October 26, 2016, 08:30:00 AM EDT=
REDWOOD CITY, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell (“anti-CSC”) and immuno-oncology product candidates, will announce financial results for the quarter ended September 30, 2016 on Tuesday, November 1, 2016. Paul J. Hastings
, Chairman and Chief Executive Officer, will host a conference call to review third quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing 1-855-420-0692 (domestic) and 1-484-756-4194 (international) using the conference ID#22966202. The webcast of the conference call will be accessible in the Investor Relations section of the OncoMed website: http://www.oncomed.com. A press release detailing third quarter results will be posted to the OncoMed website shortly before the conference call.
The web broadcast of the conference call will be available for replay through December 31, 2016 via the OncoMed website. An audio replay of the conference call can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR. OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (I/O#2) toward clinical trials in the 2016-2017 timeframe. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).